CDK4 and breast cancer: CDK4/6i induction of antitumor immunity and immune checkpoint expression in tumor cells and T cells strongly suggest the ability of CDK4/6i to skew “cold” type BC into “hot” tumor, implying their potential of being combined with ICBs [75–77, 135].